ABSTRACT

There is a substantial body of literature comprising anecdotal material and descriptions of uncontrolled and randomized controlled trials addressing the use of subanesthetic doses of ketamine for the off-label treatment of major depressive episodes. This article examines diagnostic indications for the off-label use of ketamine as an antidepressant and possible contexts in which ketamine may be trialled. Ketamine is indicated in patients who are in a major depressive episode. Most of the research data have been collected from patients with major depressive disorder, but patients with bipolar depression have also been studied. Ketamine is effective in both diagnostic groups, but its benefits are impermanent, perhaps more so in bipolar depression. There are several contexts within this diagnostic framework when a ketamine trial may be considered. These include severe depression and depression that is refractory to conventional antidepressant medication; this is because there is little purpose in trialling an experimental treatment in patients who are less severely ill and those who are antidepressant responsive. More importantly, ketamine has demonstrated efficacy in the rapid reduction of suicidal symptoms and can therefore be trialled when rapid reduction in suicidality is necessary. Likewise, because of its swift and dramatic antidepressant action, it can be trialled in patients in whom improvement is urgently desired in order to allow the patient to attend to pressing life circumstances. Some data suggest that the use of ketamine early during the course of an antidepressant trial, or as anaesthesia during electroconvulsive therapy, can improve early antidepressant outcomes. It is not clear whether the presence of psychotic symptoms is a contraindication for ketamine use. Issues related to these indications and contexts are briefly discussed.

Introduction

A previous article in this column summarized issues related to the efficacy, adverse effects, and possible mechanism(s) of action of subanesthetic dosing with ketamine in the treatment of depression. The present article examines possible diagnostic indications and clinical contexts for the use of ketamine as an off-label antidepressant (Table 1). Readers may note here that the distinction between diagnostic indications and clinical contexts was made previously with regard to electroconvulsive therapy (ECT). In explanation, depression, mania, and schizophrenia are examples of indications for ECT, and severe illness, medication-refractory illness, presence of catatonic symptoms, presence of psychotic symptoms, presence of suicidality, and the need to discharge the patient early are examples of clinical and administrative contexts in which the use of ECT may be preferred.

Diagnostic Indications

The antidepressant efficacy of subanesthetic doses of ketamine has been specifically studied in patients who were in a major depressive episode. Antidepressant benefits were observed to achieve statistical and clinical significance within 1–4 hours of ketamine administration. Such benefits peak after a day and are progressively lost 3–12 days later. Samples recruited in ketamine trials include subjects with major depressive disorder and those with bipolar depression; although the latter are a minority in terms of numbers of subjects and trials, there have been no signals suggesting poorer response or greater risks, such as that of manic switch, or other critical issues, except, perhaps, for an earlier offset of antidepressant action. Nonrefractory, mixed, and antidepressant-refractory samples have all been studied, with depression being at least moderately severe, and, more usually, severe, in all samples.

Depression with psychotic features has generally been an exclusionary condition in clinical trials of ketamine for depression. However, there have been anecdotal reports of the safe and effective use of ketamine in patients with psychotic depression, suggesting the possibility that this subgroup of patients may also benefit from a ketamine trial. At present, however, depression with psychotic features is best considered as a cautionary context for the use of ketamine.

Refractory Depression as a Clinical Context

Conventional antidepressant drugs are well established with regard to safety, efficacy, and convenience of administration for depressed patients in everyday clinical care. Ketamine may therefore be appropriate only in depressed patients who do not respond to conventional antidepressant drugs. In fact, most of the research on the off-label use of ketamine in depression has been conducted in patients in a (usually) severe antidepressant-refractory major depressive episode. There is, however, no guidance presently available that addresses where in the hierarchy of treatments an experimental treatment such as ketamine belongs in managing medication-refractory depression; patient selection, presently, is therefore a matter of judgment.
Severe Suicidal Ideation as a Clinical Context

Suicidal ideation with strong intent is a clinical emergency; depressed patients at high risk of suicide are usually managed as inpatients, with ECT commonly offered as a treatment option. ECT, however, is associated with a risk of cognitive and other adverse effects. Ketamine has demonstrated efficacy against measures of suicidality in uncontrolled studies and in randomized controlled trials (RCTs); the effect size is large, and the benefits are apparent within a day.

Small studies conducted in emergency department settings have demonstrated that the antisuicidal effect of ketamine may even be apparent within 40 minutes of treatment. The anecdotal use of ketamine as an emergency treatment for intense and persistent suicidal ideation in a young, depressed woman has also been described.

The antisuicidal effect of ketamine is probably mediated by its antidepressant effect and wears off within days to a week but may be sustained for as long as 10 days. The time thus bought could be valuable because it would allow the initiation of other antidepressant and psychosocial intervention measures, as appropriate.

Life Circumstances as a Clinical Context

In 2009, Kellner et al reported the use of ECT for an “urgent social indication.” The patient was a woman with recurrent depression who presented to the ECT services days before her daughter’s wedding. A single ECT administered with bifrontal electrode placement resulted in sufficient improvement for the woman to participate in and enjoy the family celebrations. There have been other reports, too, of the use of ECT to attenuate depression in the face of pressing life circumstances such as an examination or the patient’s own wedding.

Given the dramatic benefits associated with the off-label use of ketamine in depression, it seems logical that ketamine could be more helpful than ECT in social emergencies. There are at least 2 reasons for this assertion. One is that ketamine but not ECT is commonly associated with marked antidepressant effect after a single treatment. The other is that ECT but not ketamine is associated with cognitive adverse effects that can compromise the ability of the patient to deal with the pressing life circumstances.

Clinical Points

- The off-label use of subanesthetic doses of ketamine to treat depression may be considered in patients with major depressive disorder or bipolar disorder who are in a current major depressive episode.
- A trial of ketamine may be appropriate when depression is severe or refractory to conventional antidepressant drugs; when rapid reduction in suicidal symptoms is necessary; and when urgent improvement in depression is desired to allow patients to attend to pressing life circumstances.
- Some antidepressant outcomes may be improved by the use of ketamine early during an antidepressant course or as anesthesia during electroconvulsive therapy.

| Table 1. Possible Diagnostic Indications and Clinical Contexts for the Off-Label Use of Subanesthetic Dosing With Ketamine in Depression |
|---------------------|---------------------------------|
| A. Diagnostic indication | Major depressive episode |
| • Occurring as part of major depressive disorder |
| • Occurring as part of bipolar disorder |
| B. Contextual indications | 1. When depression is severe |
| 2. When depression is refractory to conventional antidepressant drugs |
| 3. When rapid attenuation of suicidality is specifically desired |
| 4. When rapid improvement from depression is desired for reasons related to life circumstances |
| 5. When there is a general intention to accelerate or otherwise improve efficacy outcomes with conventional antidepressant medication |
| 6. When there is a general intention to accelerate or otherwise improve efficacy outcomes with electroconvulsive therapy |
| C. Contextual caution | When depression is accompanied by psychotic symptoms |

Subcutaneous routes can be established to be as effective as administration by the intravenous route, then the treatment procedure also becomes far more convenient than ECT.

Given the transience of the antidepressant benefits of ketamine, the treatment may need to be repeated if the social context is still present at the time the benefits wear off. The value of ketamine to allow depressed patients to recover sufficiently to deal with pressing life circumstances has not been formally studied, so far, and certainly merits attention.

Antidepressant Drug Treatment Initiation as a Clinical Context

If ketamine has an acute antidepressant effect, can it accelerate recovery or otherwise improve antidepressant outcomes in nonrefractory depressed patients started on conventional antidepressant drugs? This is an important question because if the answer is yes, then ketamine augmentation could become a useful strategy to reduce the duration of suffering and disability and to hasten functional recovery in depression.

In what is possibly the only RCT on the subject published so far, Hu et al administered a single dose of intravenous ketamine or saline placebo to 27 patients with severe nonpsychotic major depressive disorder, all of whom were also prescribed escitalopram (10 mg/d). At the end of the 4-week trial, response rates (92% vs 57%) and remission rates (77% vs 14%) were significantly higher in the ketamine group relative to the placebo group. Ketamine was also associated with shorter mean time to response (6.4 vs 26.5 days) and remission (14 vs 27 days), and the effect sizes, favoring ketamine, were large, on various rating instruments.

All cause discontinuation was numerically higher with ketamine than with placebo (20% vs 7%). Whereas ketamine was associated with more adverse events, no patient dropped out because of adverse events.

In this study, 56% of the sample was classified as treatment-refractory; analyses were presented for the superiority of ketamine over placebo in the whole sample and in the refractory subgroup but not in the nonrefractory patients. Therefore, a limitation of the study is that it is...
uncertain to what extent the findings can be generalized to nonrefractory samples in routine clinical care. This, therefore, remains an important area for future investigation.

ECT Initiation as a Clinical Context

ECT is administered under anesthesia, and ketamine is an approved anesthetic agent. Might the use of ketamine in ECT anesthesia improve ECT outcomes? This question has been examined in several RCTs as well as in meta-analyses.

In one systematic review and meta-analysis, McGirr et al. identified 10 parallel-group RCTs conducted in patients with unipolar or bipolar depression. These patients had received ECT in ketamine (0.3 to 2.0 mg/kg; n = 333) or control (n = 269) arms. Ketamine had been administered either as standard (anesthesia) dose monotherapy or as low dose augmentation of sodium thiopental or propofol anesthesia. Analyses conducted at the ECT treatment endpoint found no difference between ketamine and control groups in response rates (53.9% vs 53.4%; 7 RCTs; n = 339) and remission rates (16.8% vs 18.9%; 7 RCTs; n = 339), nor did the groups differ significantly in the magnitude of antidepressant effect in either main or sensitivity analyses. Ketamine was associated with an increased risk of confusion.

In a second systematic review and meta-analysis published at approximately the same time as the previously described meta-analysis, Li et al. identified 16 RCTs with 346 and 329 patients in ketamine and control arms, respectively. The use of ketamine in the ECT anesthesia regimen was associated with significantly greater antidepressant improvement at 1–2 as well as at 3–4 week assessments. The advantage for ketamine persisted in different subgroup and sensitivity analyses.

How does one reconcile these disparate conclusions? One explanation is that Li et al. included a broader range of studies; another is that Li et al. examined early (1–2 week) outcomes whereas McGirr et al. studied only endpoint outcomes. It is possible that ketamine can improve early outcomes before the antidepressant effect of ECT manifests, and that at the end of the course, because ECT is a gold standard treatment for depression and because it is hard to improve a gold standard, a ceiling effect prevents the emergence of further benefit with ketamine.

Therefore, it appears that, at best, the use of ketamine in ECT anesthesia may carry benefits in the early part of an ECT course, but this will require further verification because the larger RCTs in the field were mostly poor in quality. Of note, a very recent RCT, not included in either meta-analysis, also did not find an advantage for the inclusion of ketamine in the ECT anesthesia.\(^{29}\) Readers who desire more information on the subject are referred to a recently published, extensive qualitative review.\(^{30}\)

Parting Notes: Use of Concurrent Medications During a Ketamine Trial

Patients treated with ketamine were medication-free in some studies,\(^{6,31}\) ongoing medications were continued unchanged in others.\(^{5,32}\) In this context, a suggestion that psychiatrists can consider is to continue necessary antidepressant and other medications during a ketamine trial, especially because maintenance antidepressant treatment will be required should the patient respond or remit. With specific reference to diagnostic subgroups, patients could need mood stabilizer and/or antipsychotic medication when the illness being treated is bipolar depression or depression with psychotic symptoms. This is to contain the hypothetical risk of a switch into mania or a ketamine-induced worsening of psychosis. Such precautions have been reported in literature.\(^{1,32}\)

REFERENCES


